XML 44 R32.htm IDEA: XBRL DOCUMENT
v3.20.2

Development Derivative Liability - Additional Information (Detail) |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Feb. 28, 2019 USD ($) Installment | Sep. 30, 2020 USD ($) | Jun. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($) | Jun. 07, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Gain/(loss) from remeasurement of development derivative liability |  | $ 2,697,000 | $ 2,770,000 | $ (68,406,000) | $ (263,000) | $ (9,104,000) | $ (736,000) | $ (62,939,000) | $ (10,103,000) |  |
Development derivative liability |  | 217,778,000 | $ 220,475,000 | $ 223,245,000 | 130,103,000 | $ 109,840,000 | $ 60,736,000 | $ 217,778,000 | 130,103,000 | $ 134,839,000 |
Level 3 [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Implied cost of borrowing discount rates |  |  |  |  |  |  |  | 16.18% |  |  |
SFJ Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from SFJ agreement | $ 60,000,000.0 |  |  |  |  |  |  | $ 20,000,000.0 | 120,000,000.0 | $ 120,000,000.0 |
Additional funding amount upon achievement of development milestones | $ 60,000,000.0 |  |  |  |  |  |  |  |  |  |
Number of milestone payments | Installment | 3 |  |  |  |  |  |  |  |  |  |
Development funding for minimum period of operating expense | 10 months |  |  |  |  |  |  |  |  |  |
Increase in additional funding for development costs |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0
Number of additional annual payments | Installment | 6 |  |  |  |  |  |  |  |  |  |
Gain/(loss) from remeasurement of development derivative liability |  | 2,700,000 |  |  | (300,000) |  |  | (62,900,000) | $ (10,100,000) |  |
Proceeds from collaborators of milestones |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |
Development derivative liability |  | $ 217,800,000 |  |  |  |  |  | $ 217,800,000 |  |  |
SFJ Agreement [Member] | Level 3 [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Implied cost of borrowing discount rates |  |  |  |  |  |  |  | 8.00% |  |  |
SFJ Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Obligated to pay initial payment | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |
Aggregate amount of additional annual payments | 226,000,000.0 |  |  |  |  |  |  |  |  |  |
SFJ Agreement [Member] | Regulatory Approval Granted by FDA and EMA [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Obligated to pay initial payment | 10,000,000.0 |  |  |  |  |  |  |  |  |  |
SFJ Agreement [Member] | Regulatory Approval Granted by FDA and EMA [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Aggregate amount of additional annual payments | $ 452,000,000.0 |  |  |  |  |  |  |  |  |  |

X
- Definition Additional funding amount upon achievement of development milestones. + References No definition available. + Details
Name: | apls_AdditionalFundingAmountUponAchievementOfDevelopmentMilestones
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate amount of additional annual payments. + References No definition available. + Details
Name: | apls_AggregateAmountOfAdditionalAnnualPayments
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development derivative liabilities noncurrent. + References No definition available. + Details
Name: | apls_DevelopmentDerivativeLiabilitiesNoncurrent
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development funding for minimum period of operating expense + References No definition available. + Details
Name: | apls_DevelopmentFundingForMinimumPeriodOfOperatingExpense
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Implied cost of borrowing discount rates. + References No definition available. + Details
Name: | apls_ImpliedCostOfBorrowingDiscountRates
Namespace Prefix: | apls_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase in additional funding for development costs. + References No definition available. + Details
Name: | apls_IncreaseInAdditionalFundingForDevelopmentCosts
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of additional annual payments. + References No definition available. + Details
Name: | apls_NumberOfAdditionalAnnualPayments
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of milestone payments. + References No definition available. + Details
Name: | apls_NumberOfMilestonePayments
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proceeds from collaborators of additional milestones. + References No definition available. + Details
Name: | apls_ProceedsFromCollaboratorsOfAdditionalMilestones
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959 + Details
Name: | us-gaap_DerivativeGainLossOnDerivativeNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_SFJAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RegulatoryAgencyAxis=apls_USFoodAndDrugAdministrationAndEuropeanMedicinesAgencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |